somatotroph comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-08-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | GHRH analog family |
| Residue count | 44 amino acids | Matches human GHRH(1-44) backbone |
| N-terminal group | trans-3-hexenoyl | Main structural difference from native hormone |
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility class | Freely soluble in water | Peptide character; less soluble in organic solvents |
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
=== Cancer === Bleomycin is mostly used to treat testicular cancer, ovarian cancer, and Hodgkin's disease, and less commonly non-Hodgkin's disease. It can be given intravenously, by intramuscular injection, or under the skin.
== Comparison with open-weights AI == The Open Source Initiative distinguishes open-source from open weights artificial intelligence when the materials needed to study and modify the model's development process are not also available.
==== Non-seasonal depression ==== Light therapy has also been suggested in the treatment of non-seasonal depression and other psychiatric mood disturbances, including major depressive disorder, bipolar disorder and postpartum depression. A meta-analysis by the Cochrane Collaboration concluded that "for patients suffering from non-seasonal depression, light therapy offers modest though promising antidepressive efficacy." A 2008 systematic review concluded that "overall, bright light therapy is an excellent candidate for inclusion into the therapeutic inventory available for the treatment of nonseasonal depression today, as adjuvant therapy to antidepressant medication, or eventually as stand-alone treatment for specific subgroups of depressed patients." A 2015 review found that supporting evidence for light therapy was limited due to serious methodological flaws. A 2016 meta-analysis showed that bright light therapy appeared to be efficacious, particularly when administered for 2–5 weeks' duration and as monotherapy.
In December 2017, Tim Hortons opened two stores in the centre of Madrid and later opened another in the city of Pozuelo de Alarcón in the Community of Madrid. The menu also includes typical Spanish drinks apart from the typical drinks of a Tim Hortons.
Sources: en.wikipedia.org
The second head of the institute was Alexander Bogomolets (see further). 1930s Beginning of attempts of rejuvenation by methods of cell injections. A special role belongs here to the Swiss physician Paul Niehans – he was not the first but he was the one who developed this approach the most. Among his patients there were many famous people (including Winston Churchill, Charles de Gaulle, Pope Pius XII). So, in 1952, about 3000 injections of about 10 cm3 of cell suspension were reported. As a consequence, cell therapy and regenerative medicine were formed. Since the 1960s, attempts have been made to inject not only whole cells but also their constituent parts (such as isolated DNA and RNA). But usage of embryonic drugs sometimes caused serious complications, so the American association of physicians recognized the method of cell therapy as dangerous. 1930 The first world's journal about aging and longevity. It was established in Japan and has the name Acta Gerontologica Japonica (Yokufuen Chosa Kenkyu Kiyo). 1933 The first institute in the world dedicated to study of aging. It was created in Kishinev (at that time inside the Kingdom of Romania) by Dimu Kotsovsky. Initially the institute was maintained by his own means, and was subsequently recognized by the Romanian government. The name is Romanian: Institutul Pentru Studierea si Combaterea Batranetii = German: Institut für Altersforschung und Altersbekämpfung = Institute for The Study and Combat of Aging.
=== Hilary Wyndham === Hilary Wyndham (Mark Dexter) is a MD of the FX desk at Pierpoint. Throughout the first season, he is shown to be a more measured leader than his subordinate Kenny, an alcoholic and a bully who repeatedly subjects Yasmin to verbal abuse. However, nearing reduction-in-force (RIF) day, Hilary advises Yasmin not to report Kenny's behavior, telling her that being a "team player" would benefit her career prospects. Yasmin caves to Hilary's advice during her RIF interview when she denies having any negative experiences at Pierpoint, and Hilary vouches for her, ensuring that she is hired. In series 2, Hilary becomes paranoid about contracting COVID-19 at the office, wearing a mask to work and exhibiting germaphobe tendencies. Ironically, it is he who ends up falling ill and having to take time off from the office. Yasmin tells Hilary that she will be spending less time on the FX desk as she explores a move to the Private Wealth Management (PWM) division; Hilary, feeling numb and burnt out from the job, grants her his blessing. Hilary briefly reappears in series 4, now working for the Railways Pension Scheme (RPS); Eric calls him to invest in his and Harper's new short-only fund, SternTao, but Hilary kindly declines, stating that the RPS doesn't share their appetite for risk.
== Animal studies == Meso-zeaxanthin has been tested for animal toxicity by several research teams, who report a lack of toxicity. The NOAEL ('No Observed-Adverse-Effect Level') of meso-zeaxanthin is far greater than doses used in dietary supplements. In 2016, the GRAS ('Generally Regarded As Safe') status of meso-zeaxanthin was acknowledged by the FDA.[1]
== Further reading == Bard, Allen J.; Larry R. Faulkner (2000-12-18). Electrochemical Methods: Fundamentals and Applications (2 ed.). Wiley. ISBN 978-0-471-04372-0. Zoski, Cynthia G. (2007-02-07). Handbook of Electrochemistry. Elsevier Science. ISBN 978-0-444-51958-0. Kissinger, Peter; William R. Heineman (1996-01-23). Laboratory Techniques in Electroanalytical Chemistry, Second Edition, Revised and Expanded (2 ed.). CRC. ISBN 978-0-8247-9445-3. Gosser, David K. (1993-09-20). Cyclic Voltammetry Simulation and Analysis of Reaction Mechanisms. VCH. ISBN 978-1-56081-026-1. Compton, Richard D.; Craig E. Banks (2010-11-15). Understanding Voltammetry (2 ed.). Imperial College Press. ISBN 978-1848165854.
=== Amino acid enrichment for certain functional categories of LCRs === A bioinformatics analysis of prokaryotic LCRs identified 5 types of amino acid enrichment, for certain functional categories of LCRs:
Sources: en.wikipedia.org
In June 2015, the United States Office of Personnel Management (OPM) announced that it had been the target of a data breach targeting the records of as many as four million people. Later, FBI Director James Comey put the number at 18 million. The Washington Post has reported that the attack originated in China, citing unnamed government officials. Operation Shady RAT is a series of cyber attacks starting mid-2006, reported by Internet security company McAfee in August 2011. China is widely believed to be the state actor behind these attacks which hit at least 72 organizations including governments and defense contractors. The 2018 cyberattack on the Marriott hotel chain that collected personal details of roughly 500 million guests is now known to be a part of a Chinese intelligence-gathering effort that also hacked health insurers and the security clearance files of millions more Americans, The hackers, are suspected of working on behalf of the Ministry of State Security (MSS), the country's Communist-controlled civilian spy agency. On 14 September 2020, a database showing personal details of about 2.4 million people around the world was leaked and published. A Chinese company, Zhenhua Data compiled the database. According to the information from "National Enterprise Credit Information Publicity System", which is run by State Administration for Market Regulation in China, the shareholders of Zhenhua Data Information Technology Co., Ltd. are two natural persons and one general partnership enterprise whose partners are natural persons.
In contrast to other mechanical disruption methods the Microfluidizer breaks the cell membranes efficiently but gently, resulting in relatively large cell wall fragments (450 nm), and thus making it easier to separate the cell contents. This can lead to shorter filtration times and better centrifugation separation. Microfluidizer technology scales from one milliliter to thousands of liters.
=== Novel biopharmaceuticals === Simultaneous to its significant increase in global market share, Biocon began increasing its development of biologics, which are more costly and technologically challenging to produce than small molecule drugs. Notable examples include the monoclonal antibodies (mAb) ALZUMAb for psoriasis in 2013, CANMAb to treat breast cancer in 2014, and the ledipasvir-sofosbuvir combination CIMIVIR-L for hepatitis C in 2015.
Representatives of member and observer countries meet in specialised committees on specific policy areas, such as economics, trade, science, employment, education, development assistance or financial markets. There are about 200 committees, working groups and expert groups. Committees discuss policies and review progress in the given policy area.
Sources: en.wikipedia.org
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.
It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.
The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.